Reliability and validity of SF-12v2 among adults with self-reported cancer
- PMID: 29366669
- PMCID: PMC7301412
- DOI: 10.1016/j.sapharm.2018.01.007
Reliability and validity of SF-12v2 among adults with self-reported cancer
Abstract
Background: The SF-12v2 has been validated in general population and other conditions but the evidence is limited in Americans with cancer.
Objective: To assess reliability and validity of SF-12v2 among adults with self-reported cancer using the Medical Expenditure Panel Survey (MEPS).
Methods: Self-reported cancer participants (SCPs) were identified from 2003 MEPS. SF-12v2 was administered as part of self-administered questionnaires. Physical (PCS12) and mental (MCS12) component scores of SF-12v2 were evaluated for reliability (internal consistency, test-retest) and validity (convergent, discriminant, predictive, concurrent).
Results: 420 SCPs were identified with average age of 59.3 years (SE = 0.9). 10.7% had multiple cancers (>1) and 52% had at least one other chronic condition (OCC). Average PCS12 and MCS12 were 45.09 (SE = 0.5) and 50.75 (SE = 0.5). PCS12 and MCS12 demonstrated high internal consistency (αPCS12 = 0.89; αMCS12 = 0.88), acceptable test-retest reliability (ICCPCS12 = 0.82; ICCMCS12 = 0.73), strongly correlated with most of the expected EQ-5D domains (r = 0.51-0.71), and demonstrated strong convergent validity on perceived health (r = 0.61) and perceived mental health (r = 0.52). PCS12 and MCS12 were able to discriminate between groups with and without physical/cognitive limitations. Only PCS12 was negatively correlated with number of OCCs.
Conclusion: The SF-12v2 is a reliable and valid instrument to quantify health-related quality of life among adults with self-reported cancer.
Keywords: Cancer; Psychometrics; Quality of life; Reliability and validity; SF-12.
Copyright © 2018. Published by Elsevier Inc.
Conflict of interest statement
Conflict of Interest
Dr. Hayes was supported by the Translational Training in Addiction [1T32 DA 022981]. Dr. Payakachat received an honorarium for service as a paid consultant to Roche Ltd., service as a consultant to CBPartners, and ownership of stock in Pfizer. Others authors report no conflicts of interest.
Figures
References
-
- Fujisawa D, Inoguchi H, Shimoda H, et al. Impact of depression on health utility value in cancer patients. Psychooncology. 2016;25:491–495. - PubMed
-
- Wedding U, Pientka L, Höffken K. Quality-of-life in elderly patients with cancer: A short review. Eur J Cancer. 2007;43:2203–2210. - PubMed
-
- Ware J How to Score Version 2 of the SF-12 Health Survey (with a Supplement Documenting Version 1). Lincoln R.I.;Boston Mass.: QualityMetric Inc.;Health Assessment Lab; 2005.
-
- Cheak-Zamora NC, Wyrwich KW, McBride TD. Reliability and validity of the SF-12v2 in the medical expenditure panel survey. Qual Life Res. 2009;18:727–735. - PubMed
-
- Smedt D De, Clays E, Doyle F, et al. Validity and reliability of three commonly used quality of life measures in a large European population of coronary heart disease patients. Int J Cardiol. 2008;167:2294–2299. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
